ALK launches tablet vaccine for tree pollen allergy

The allergy solutions company ALK launches its tablet vaccine for tree pollen allergy in Canada, where more than seven million people suffer from tree pollen allergy. The launch completes ALK's tablet portfolio in Canada, where the expected sales potential is in the high figures.

Photo: ALK / PR

Barely half-a-year after the Canadian health authorities approved the allergy company ALK's tablet vaccine for tree pollen allergy, the first vaccines are now available on the market in Canada.

The treatment, which is being marketed under the name Itulazax in Europe, is sold as Itulatek in Canada, and it works against birch pollen, hazel pollen and elm pollen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs